ERBB2 and breast cancer: Indeed, a retrospective analysis of 173 patients with HER2 + BC treated with adjuvant paclitaxel plus trastuzumab first reported a 3-year disease-free survival (DFS) and recurrence-free interval (RFI) rate of 96.6%18.